PLGA-based nanoparticles: A new paradigm in biomedical applications

Danhier, 2012, based nanoparticles: an overview of biomedical applications, J. Control. Release, 161, 505, 10.1016/j.jconrel.2012.01.043 Liu, 2007, Nanomedicine for drug delivery and imaging: a promising avenue for cancer therapy and diagnosis using targeted functional nanoparticles, Int. J. Cancer, 120, 2527, 10.1002/ijc.22709 Wickline, 2007, Molecular imaging and therapy of atherosclerosis with targeted nanoparticles, J. Magn. Reson. Imaging, 25, 667, 10.1002/jmri.20866 Langer, 1976, Polymers for the sustained release of proteins and other macromolecules, Nature, 263, 797, 10.1038/263797a0 Dragan, 2009, Poly(lactide-co-glycolide)-based micro and nanoparticles for the controlled drug delivery of vitamins, Curr. Nanosci, 5, 1, 10.2174/157341309787314566 Choi, 2012, Recent advances in PLGA particulate systems for drug delivery, J. Pharm. Investig, 42, 155, 10.1007/s40005-012-0024-5 Locatelli, 2012, Biodegradable PLGA-b-PEG polymeric nanoparticles: synthesis, properties, and nanomedical applications as drug delivery systems, J. Nanoparticle Res, 14, 10.1007/s11051-012-1316-4 Mirakabad, 2014, PLGA-based nanoparticles as cancer drug delivery systems, Asian Pac. J. Cancer Prev, 15, 517, 10.7314/APJCP.2014.15.2.517 Makadia, 2011, Poly Lactic-co-Glycolic acid (PLGA) as biodegradable controlled drug delivery carrier, Polymers (Basel), 3, 1377, 10.3390/polym3031377 Prokop, 2008, Nanovehicular intracellular delivery systems, J. Pharm. Sci, 97, 3518, 10.1002/jps.21270 Schliecker, 2003, Characterization of a homologous series of D,L-lactic acid oligomers; a mechanistic study on the degradation kinetics in vitro, Biomaterials, 24, 3835, 10.1016/S0142-9612(03)00243-6 Acharya, 2011, PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect, Adv. Drug Deliv. Rev, 63, 170, 10.1016/j.addr.2010.10.008 Siegel, 2006, Effect of drug type on the degradation rate of PLGA matrices, Eur. J. Pharm. Biopharm, 64, 287, 10.1016/j.ejpb.2006.06.009 Passerini, 2001, An investigation into the effects of residual water on the glass transition temperature of polylactide microspheres using modulated temperature DSC, J. Control. Release, 73, 111, 10.1016/S0168-3659(01)00245-0 Panagi, 2001, Effect of dose on the biodistribution and pharmacokinetics of PLGA and PLGA-mPEG nanoparticles, Int. J. Pharm, 221, 143, 10.1016/S0378-5173(01)00676-7 Jain, 2000, The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices, Biomaterials, 21, 2475, 10.1016/S0142-9612(00)00115-0 Mao, 2007, Effect of WOW process parameters on morphology and burst release of FITC-dextran loaded PLGA microspheres, Int. J. Pharm, 334, 137, 10.1016/j.ijpharm.2006.10.036 Hua, 2003, facile preparation of highly interconnected macroporous PLGA scaffolds by liquid-liquid phase separation of a PLGA-dioxane-water ternary system, Polymer (Guildf.), 44, 1911, 10.1016/S0032-3861(03)00025-9 D'Mello, 2006 Lambert, 2001, Nanoparticulate systems for the delivery of antisense oligonucleotides, Adv. Drug Deliv. Rev, 47, 99, 10.1016/S0169-409X(00)00116-2 Fessi, 1989, Nanocapsule formation by interfacial polymer deposition following solvent displacement, Int. J. Pharm, 55, R1, 10.1016/0378-5173(89)90281-0 Govender, 1999, PLGA nanoparticles prepared by nanoprecipitation: drug loading and release studies of a water soluble drug, J. Control. Release, 57, 171, 10.1016/S0168-3659(98)00116-3 Jeong, 2001, Preparation of poly(dl-lactide-co-glycolide) nanoparticles without surfactant, J. Appl. Polym. Sci, 80, 2228, 10.1002/app.1326 Kostog, 2010, Pure cellulose nanoparticles from trimethylsilyl cellulose, Macromol. Symp, 294, 96, 10.1002/masy.200900095 Nie, 2008, PLGA/chitosan composites from a combination of spray drying and supercritical fluid foaming techniques: new carriers for DNA delivery, J. Control. Release, 129, 207, 10.1016/j.jconrel.2008.04.018 Mishima, 2008, Biodegradable particle formation for drug and gene delivery using supercritical fluid and dense gas, Adv. Drug Deliv. Rev, 60, 411, 10.1016/j.addr.2007.02.003 Rao, 2011, Polymer nanoparticles: Preparation techniques and size-control parameters, Elsevier, 36, 887 Sun, 2002, Preparation and processing of nanoscale materials by supercritical fluid technology, 491 Mittal, 2007, Estradiol loaded PLGA nanoparticles for oral administration: effect of polymer molecular weight and copolymer composition on release behavior in vitro and in vivo, J. Control. Release, 119, 77, 10.1016/j.jconrel.2007.01.016 Garinot, 2007, PEGylated PLGA-based nanoparticles targeting M cells for oral vaccination, J. Control. Release, 120, 195, 10.1016/j.jconrel.2007.04.021 Esmaeili, 2008, PLGA nanoparticles of different surface properties: preparation and evaluation of their body distribution, Int. J. Pharm, 349, 249, 10.1016/j.ijpharm.2007.07.038 Bala, 2004, PLGA nanoparticles in drug delivery: the state of the art, Crit. Rev. Ther. Drug Carrier Syst, 21, 387, 10.1615/CritRevTherDrugCarrierSyst.v21.i5.20 Zhang, 2006, The drug encapsulation efficiency, in vitro drug release, cellular uptake and cytotoxicity of paclitaxel-loaded poly(lactide)-tocopheryl polyethylene glycol succinate nanoparticles, Biomaterials, 27, 4025, 10.1016/j.biomaterials.2006.03.006 Yang, 2007, Tumor necrosis factor alpha blocking peptide loaded PEG-PLGA nanoparticles: preparation and in vitro evaluation, Int. J. Pharm, 331, 123, 10.1016/j.ijpharm.2006.09.015 Kumari, 2010, Biodegradable polymeric nanoparticles based drug delivery systems, Colloids Surf. B. Biointerfaces, 75, 1, 10.1016/j.colsurfb.2009.09.001 Jain, 2011, Engineered PLGA nanoparticles: an emerging delivery tool in cancer therapeutics, Crit. Rev. Ther. Drug Carrier Syst, 28, 1, 10.1615/CritRevTherDrugCarrierSyst.v28.i1.10 Lu, 2005, Cationic albumin conjugated pegylated nanoparticle with its transcytosis ability and little toxicity against blood-brain barrier, Int. J. Pharm, 295, 247, 10.1016/j.ijpharm.2005.01.043 Gref, 2000, ‘Stealth’ corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption, Colloids Surf. B. Biointerfaces, 18, 301, 10.1016/S0927-7765(99)00156-3 Danhier, 2009, Paclitaxel-loaded PEGylated PLGA-based nanoparticles: in vitro and in vivo evaluation, J. Control. Release, 133, 11, 10.1016/j.jconrel.2008.09.086 Gref, 1994, Biodegradable long-circulating polymeric nanospheres, Science, 263, 1600, 10.1126/science.8128245 Gryparis, 2007, Anticancer activity of cisplatin-loaded PLGA-mPEG nanoparticles on LNCaP prostate cancer cells, Eur. J. Pharm. Biopharm, 67, 1, 10.1016/j.ejpb.2006.12.017 Senthilkumar, 2008, Long circulating PEGylated poly(D,L-lactide-co-glycolide) nanoparticulate delivery of Docetaxel to solid tumors, J. Drug Target, 16, 424, 10.1080/10611860802088598 Betancourt, 2009, PEGylation strategies for active targeting of PLA/PLGA nanoparticles, J. Biomed. Mater. Res. A, 91, 263, 10.1002/jbm.a.32247 Fredenberg, 2011, The mechanisms of drug release in poly(lactic-co-glycolic acid)-based drug delivery systems–a review, Int. J. Pharm, 415, 34, 10.1016/j.ijpharm.2011.05.049 Marucci, 2009 Shenderova, 1999, The acidic microclimate in poly(lactide-co-glycolide) microspheres stabilizes camptothecins, Pharm. Res, 16, 241, 10.1023/A:1018876308346 Dunne, 2000, Influence of particle size and dissolution conditions on the degradation properties of polylactide-co-glycolide particles, Biomaterials, 21, 1659, 10.1016/S0142-9612(00)00040-5 Berchane, 2007, Effect of mean diameter and polydispersity of PLG microspheres on drug release: experiment and theory, Int. J. Pharm, 337, 118, 10.1016/j.ijpharm.2006.12.037 Amann, 2010, In vitro-in vivo correlations of scalable PLGA-risperidone implants for the treatment of schizophrenia, Pharm. Res, 27, 1730, 10.1007/s11095-010-0152-4 Lu, 2000, In vitro and in vivo degradation of porous poly(DL-lactic-co-glycolic acid) foams, Biomaterials, 21, 1837, 10.1016/S0142-9612(00)00047-8 Zolnik, 2007, Effect of acidic pH on PLGA microsphere degradation and release, J. Control. Release, 122, 338, 10.1016/j.jconrel.2007.05.034 Kuppens, 2005, Oral bioavailability of docetaxel in combination with OC144-093 (ONT-093), Cancer Chemother. Pharmacol, 55, 72, 10.1007/s00280-004-0864-4 Hennessy, 2007, A primer on the mechanics of P-glycoprotein the multidrug transporter, Pharmacol. Res, 55, 1, 10.1016/j.phrs.2006.10.007 Li, 2012, Bypassing multidrug resistance in human breast cancer cells with lipid/polymer particle assemblies, Int. J. Nanomedicine, 7, 187 Langer, 1998, Drug delivery and targeting, Nature, 392, 5 Danhier, 2010, To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery, J. Control. Release, 148, 135, 10.1016/j.jconrel.2010.08.027 Pastorino, 2006, Targeting liposomal chemotherapy via both tumor cell-specific and tumor vasculature-specific ligands potentiates therapeutic efficacy, Cancer Res, 66, 10073, 10.1158/0008-5472.CAN-06-2117 Folkman, 1971, Transplacental carcinogenesis by stilbestrol, N. Engl. J. Med, 285, 404, 10.1056/NEJM197108122850711 Sah, 2013, Concepts and practices used to develop functional PLGA-based nanoparticulate systems, Int. J. Nanomedicine, 8, 747, 10.2147/IJN.S40579 Kou, 2007, Preparation and characterization of paclitaxel-loaded PLGA nanoparticles coated with cationic SM5-1 single-chain antibody, J. Biochem. Mol. Biol, 40, 731 Dhar, 2008, Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles, Proc. Natl. Acad. Sci. U.S.A., 105, 17356, 10.1073/pnas.0809154105 Danhier, 2009, Targeting of tumor endothelium by RGD-grafted PLGA-nanoparticles loaded with paclitaxel, J. Control. Release, 140, 166, 10.1016/j.jconrel.2009.08.011 Diez, 2009, In vivo targeted gene delivery by cationic nanoparticles for treatment of hepatocellular carcinoma, J. Gene Med, 11, 38, 10.1002/jgm.1273 Gvili, 2007, Poly(D,L-lactide-co-glycolide acid) nanoparticles for DNA delivery: waiving preparation complexity and increasing efficiency, Biopolymers, 85, 379, 10.1002/bip.20697 Nafee, 2007, Chitosan-coated PLGA nanoparticles for DNA/RNA delivery: effect of the formulation parameters on complexation and transfection of antisense oligonucleotides, Nanomedicine, 3, 173, 10.1016/j.nano.2007.03.006 Nguyen, 2008, Fast degrading polyesters as siRNA nano-carriers- for pulmonary gene therapy, J. Control Rel, 132, 243, 10.1016/j.jconrel.2008.06.010 Wang, 2008, Formulation of superparamagnetic iron oxides by nanoparticles of biodegradable polymers for magnetic resonance imaging, Adv. Funct. Mater, 18, 308, 10.1002/adfm.200700456 Janib, 2010, Imaging and drug delivery using theranostic nanoparticles, Adv. Drug Deliv. Rev, 62, 1052, 10.1016/j.addr.2010.08.004 Singh, 2011, Composite polymeric magnetic nanoparticles for co-delivery of hydrophobic and hydrophilic anticancer drugs and MRI imaging for cancer therapy, ACS Appl. Mater. Interfaces, 3, 842, 10.1021/am101196v Dailey, 2006, Investigation of the proinflammatory potential of biodegradable nanoparticle drug delivery systems in the lung, Toxicol. Appl. Pharmacol, 215, 100, 10.1016/j.taap.2006.01.016